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Introduction
• Keloids =potentially genetically-driven benign tumor-like
scars that grow beyond wound borders that appear to
preferentially affect African Americans
• Why patients care à Range from asymptomatic, small
papules to large, painful, itchy, raised plaques that are
aesthetically unpleasing to patients
• Why we should care à Despite the great effect that these
lesions can have on a patient’s quality of life, there is still a
very limited amount of research literature on how to treat
them most effectively
• WE STILL DON’T KNOW WHAT TREATMENT IS MOST
EFFECTIVE!

Introduction
• No single treatment modality has proven effective, so we
need adjuvant therapies
Prophylaxis
Topical Silicone Gel
Sheets

Monotherapy

Multimodal Therapies

Intralesional Triamcinolone

Injection of triamcinolone + PRP intraoperatively
Brachytherapy during excision

Surgical excision

Excision + PRP + post-op superficial radiation

Extracorporeal Shockwave Therapy

Triamcinolone injections + PRP application or 5FU injection

Cryotherapy

Laser-assisted delivery of injected or topical
steroids

• OBJECTIVE: determine what currently available treatment
works best for keloid patients in reducing the size and
symptoms of their keloids

– Hope to build upon this information in the future as we explore new
treatment options

Objectives
& Hypothesis
• Research Question
– How do patient keloid outcomes post-ILK
injections compare with outcomes post-surgical
excision?

• Hypothesis
– ILK injections lead to better keloid outcomes
than surgical excision.

Approach & Results
• Study design: Retrospective chart review with phone
surveys

– Retrospective study revealed the need for prospective
phone surveys due to lack of detailed information in and
inconsistencies between encounter notes

• Population/study sample: 504 keloid patients treated
at Jefferson in the past 2 years
• Comparison group: Patients receiving ILK vs. patients
undergoing surgical excision
• Outcome measures: % change in lesion size, change
in symptoms (pruritis, pain; on a scale of 0-10)
• Data source and collection: phone surveys based on
preliminary data collection from retrospective chart
review, collected in an Excel spreadsheet

Approach & Results
• Analysis

– Pie charts, bar graphs
– 2-tailed t-test with equal variance

• Findings

– 84 patients with 114 keloids responded
– 16 keloids were excised and 90 were treated with Kenalog
– Size change findings

• Excision and Kenalog comparably produced some decrease in size
• More excised keloids resolved completely vs. more Kenalog-treated keloids decreased less
than 50% in size
• Excision group showed more cases of increased keloid size

– Symptom score findings

• No significant difference in pruritus scores
• Excisions reduced pain scores significantly
• No significant differences in either symptom score within keloid location groupings

While excised keloids and Kenalog-injected keloids comparably produced some
decrease in size (81% vs. 78%), more excised keloids resolved completely (37%
vs. 10%) and more Kenalog-treated keloids decreased less than 50% in size (41%
vs. 19%). However, the excision group also showed more cases of increased keloid
size (13% vs. 4%).

Comparison of symptom scores showed no significant difference in pruritus
scores (p = 0.159), but demonstrated that excisions reduced pain scores
significantly (p = 0.010).

Symptom Scores by Location

Symptom Scores by Location

Conclusions
• The results of this study suggest that excised keloids
produce better size and pain reduction than Kenaloginjected keloids
• These findings are the opposite of what was expected
based on clinical experience and current literature
– Literature suggests that 50-80% of excised keloids recur

• BUT, outcome analysis was limited by the survey
responses collected, as consenting patients mainly
received Kenalog treatments (90 vs. 16)
• Further research is necessary to accurately determine
which treatment modality is most effective before
using this data to affect clinical practice

Future Directions
• Enroll more patients through in-person
surveys in the keloid clinic (especially excision
patients to allow for a better comparison)
• Clinical trials of new therapies, perhaps
starting with more common and bothersome
keloid locations (ears, chest/breast)
– Laser-delivered 5-FU
– ILK+5-FU injections
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